Free tool
FAERS Monitor: Doptelet Sprinkle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219696 or its brand name (Doptelet Sprinkle, Avatrombopag Maleate). Reports on generic versions are filed under their own applications.
Reports
375
Serious
340
91% of reports
Hospitalization
145
Death reported
49
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use67
- drug ineffective46
- platelet count decreased34
- therapy non-responder26
- immune thrombocytopenia23
- thrombocytopenia19
- death16
- infection16
- diarrhoea15
- pneumonia15
- abdominal pain14
- myelofibrosis14
- platelet count abnormal14
- pulmonary embolism14
- neutrophil count decreased13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 13 |
| 2022 | 33 |
| 2023 | 57 |
| 2024 | 91 |
| 2025 | 102 |
| 2026 | 71 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,784 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune thrombocytopeniaSignal | 23 | 283.2 | 190.4 | 6,158 |
| myelofibrosisSignal | 14 | 260.9 | 155.8 | 3,354 |
| platelet count abnormalSignal | 14 | 130.2 | 77.8 | 1,665 |
| therapy non-responderSignal | 26 | 32.5 | 22.4 | 763 |
| platelet count decreasedSignal | 34 | 17.9 | 13.0 | 528 |
| neutrophil count decreasedSignal | 13 | 17.9 | 10.5 | 191 |
| thrombocytopeniaSignal | 19 | 9.5 | 6.1 | 137 |
| pulmonary embolismSignal | 14 | 8.3 | 4.9 | 83 |
| infectionSignal | 16 | 6.2 | 3.8 | 65 |
| off label useSignal | 67 | 4.3 | 3.5 | 173 |
| abdominal painSignal | 14 | 3.4 | 2.0 | 21 |
| pneumoniaSignal | 15 | 2.6 | 1.6 | 13 |
| drug ineffective | 46 | 2.0 | 1.5 | 22 |
| diarrhoea | 15 | 1.3 | 0.8 | 1 |
| death | 16 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.